NCT Number: NCT00340054
Developing Interview Questions to Estimate Workplace Exposure to Electric and Magnetic Fields
RATIONALE: Electric and magnetic fields may increase the risk of cancer. Developing interview questions that accurately estimate a person's exposure to electric and magnetic fields may help doctors learn about the long-term effects of workplace exposure.
PURPOSE: This clinical trial is developing interview questions that can be used in estimating workplace exposure to electric and magnetic fields.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Exponent, Inc., Menlo Park, California, United States
About this study
OBJECTIVES:
- Validate an interview-based electric and magnetic field exposure (EMF) assessment algorithm against measurements of the time-weighted average magnetic field magnitude used in previous epidemiologic studies.
- Calibrate the parameters in the algorithm in order to improve the exposure estimates.
- Correlate EMF exposure estimates from the algorithm with biologically based metrics measured by new instrumentation.
OUTLINE: Participants respond to questions during a 5- to 15-minute telephone interview concerning workplace exposure to electric and magnetic (EMF) fields. Data is collected during the interview using an exposure assessment algorithm designed to estimate EMF workplace exposure based on participants' responses. The interview-based estimates are then validated against actual field measurements of magnetic field exposure captured by Emdex multiwave monitors located at participating sites.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
DISEASE CHARACTERISTICS:
- Meets 1 of the following occupation criteria:
- Three occupations that primarily work in offices at Lawrence Livermore National Laboratories (LLNL)
- Three occupations that do nonelectric manual work (e.g., machinists and laborers) at LLNL
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Treatment and study plan
study of high risk factors
ProcedurePrimary outcomes
-
Validation of an interview-based electric and magnetic field (EMF) exposure assessment algorithm
-
Calibration of algorithm parameters
-
Correlation between EMF exposure estimates from the algorithm with biologically based metrics measured by new instrumentation
Sponsors and collaborators
Lead sponsor
National Institutes of Health Clinical Center (CC)
Nih
Collaborators
- National Cancer Institute (NCI)
Registry information
Official study title
Assessment of Occupational EMF Exposure - Validation of Interview Procedures Used in Brain Tumor Study
Important dates
- Study start
- 2005
- Study completion
- 2007
- First posted
- Jun 21, 2006
- Registry last updated
- Mar 8, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
NCT03150862
Astrocytoma, Brain Diseases
Tucson, Arizona, United States
View Trial DetailsCilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer
NCT00884598
Brain Diseases, Brain Neoplasms
Mannheim, Germany
View Trial DetailsIodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
NCT00445965
Adnexal Diseases, Astrocytoma
New York, United States
View Trial DetailsInterferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas
NCT00002965
Brain Diseases, Brain Neoplasms
Houston, Texas, United States
View Trial Details